NCT07798323 · Scott Raymond
Noninvasive Imaging Biomarkers of Treatable Macrovascular Disease in Age-related Macular Degeneration.
What this study is about
The purpose of this forward-looking study is to investigate whether ophthalmic artery stenosis (narrowing of the ophthalmic artery) contributes to the development and progression of geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD).
View original scientific description
The purpose of this prospective study is to investigate whether ophthalmic artery stenosis (narrowing of the ophthalmic artery) contributes to the development and progression of geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD).
Primary outcome measures
To demonstrate the ability to quantify ophthalmic artery stenosis using a commercially available, non-invasive imaging modality, PC-CTA.
Time frame: From enrollment to the end of the 12-month study period.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- 50-80 years of age
- All genders
- Asymmetric dry AMD with geographic atrophy in at least one eye and reduced disease severity in the other eye according to International Classification of Disease (ICD) codes
- Treated at the Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
Exclusion criteria
- Poor image quality that limits quantification
- GA extending beyond the borders of the SDOCT field of view.
- Bilateral symmetric geographic atrophy.
- Diagnosis of wet AMD.
- Any retinal fluid at baseline.
- Other concurrent retinal diseases
- Vitreoretinal surgery.
- Allergy to iodinated contrast agents.
- Chronic kidney disease with eGFR \< 60
Where
- Cleveland, Ohio
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Sep 1, 2026 · Source of record for eligibility and locations